The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome
Recruiting
Observational Study
Tako Tsubo Cardiomyopathy
Microvascular Dysfunction
CD34+ Stem Cells
Heart Failure
Cardiac Contractility Recovery
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 40 (estimated)
- Sponsor
- University Medical Centre Ljubljana · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The underlying mechanisms of microvascular dysfunction in Takotsubo cardiomyopathy remain incompletely understood. As CD34+ cells are essential to coronary microvascular homeostasis we will investigate the potential association between CD34+ cell count and changes in left ventricular function in patients with Takotsubo cardiomyopathy at baseline and 6-month follow-up.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Minimum age 18 years
* Established TTS per InterTak registry criteria
* Signed consent form
Exclusion Criteria:
* Patients under the age of 18 years
* Ischemic heart disease with at least one complete total occlusion
* Other concurrent cardiomyopathies
* Active infectious my…
Contacts